185 studies found for:    N08C9
Show Display Options
Rank Status Study
1 Active, not recruiting Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy
Conditions: Diarrhea;   Gastrointestinal Complications;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sulfasalazine;   Other: placebo
2 Unknown  Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression
Condition: Depression
3 Enrolling by invitation A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Condition: Hepatitis C, Chronic
4 Enrolling by invitation Gilead Sustained Virologic Response (SVR) Registry
Condition: Hepatitis C, Chronic
5 Completed
Has Results
Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness
Conditions: Venous Thrombosis;   Pulmonary Embolism
Interventions: Drug: Apixaban;   Drug: Enoxaparin
6 Completed
Has Results
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
Conditions: Atrial Fibrillation;   Atrial Flutter
Interventions: Drug: warfarin;   Drug: apixaban
7 Completed
Has Results
Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: FDG-PET;   Drug: Pemetrexed;   Drug: Sirolimus;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic acid tablets;   Drug: Dexamethasone tablets
8 Completed
Has Results
Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma
Conditions: Carcinoma, Renal Cell;   Kidney Neoplasms
Interventions: Drug: Interferon Alfa;   Drug: CCI-779;   Drug: Interferon Alfa and CCI-779
9 Recruiting Neuropsychological Changes in Patients Receiving Radiation Therapy for Brain Metastases
Conditions: Brain Metastasis;   Cancer
10 Completed Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59
Condition: Influenza
Interventions: Biological: MF-59;   Biological: A/Anhui/05;   Drug: Placebo
11 Completed
Has Results
Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease
Condition: Hepatitis C, Chronic
Interventions: Drug: eltrombopag;   Drug: placebo
12 Recruiting Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
Condition: Hyperlipidemia
Interventions: Drug: Part A, Atorvastatin;   Other: Part A, Placebo (administered orally);   Drug: Part B, Evolocumab;   Other: Part B, Placebo (administered orally);   Drug: Part B, Ezetimibe;   Other: Part B, Placebo (administered subcutaneously);   Drug: Part C, Evolocumab
13 Recruiting Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Condition: Dyslipidemia
Interventions: Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy
14 Active, not recruiting
Has Results
A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.
Condition: Newly Diagnosed Multiple Myeloma
Interventions: Drug: Lenalidomide:  Double-blind Induction;   Drug: Melphalan;   Drug: Prednisone;   Drug: Aspirin;   Drug: Placebo;   Drug: Lenalidomide:  Double-blind Maintenance;   Drug: Lenalidomide:  Open-label
15 Recruiting GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound
Condition: Hypercholesterolemia
Interventions: Biological: Evolocumab (AMG 145);   Other: Placebo
16 Recruiting Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders
Condition: Severe Familial Hypercholesterolemia
Intervention: Biological: Evolocumab (AMG145)
17 Recruiting Open Label Study of Long Term Evaluation Against LDL-C Trial-2
Condition: Hyperlipidemia and Mixed Dyslipidemia
Interventions: Biological: evolocumab (AMG 145) and standard of care;   Other: Standard of care
18 Active, not recruiting Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Condition: Hepatitis C
Intervention: Drug: Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)
19 Active, not recruiting Long-term Safety and Tolerability of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)
Condition: Hypercholesterolemia
Interventions: Other: placebo;   Drug: alirocumab SAR236553 (REGN727)
20 Completed
Has Results
Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock
Condition: Sepsis
Interventions: Drug: Drotrecogin alfa (activated);   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years